Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604406 · ClinicalTrials.gov registry record · Phase 2
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
A Phase 2 study of Rheumatoid Arthritis and Herpes Zoster, sponsored by Kevin Winthrop.
- Active
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
- 5
- Study locations
NCT03604406 is a Phase 2 study of Rheumatoid Arthritis and Herpes Zoster that is active but no longer recruiting, run by Kevin Winthrop. The registered enrollment target is 154 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03604406, a Phase 2 study of Rheumatoid Arthritis and Herpes Zoster, is active but no longer recruiting, sponsored by Kevin Winthrop.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
- 5
- Study locations
Study Summary
This investigator-initiated study will serve as a sub-study for the American College of Rheumatology-sponsored VERVE protocol currently funded by the NIH. This double-blinded multicenter randomized pragmatic trial is designed to determine whether Zostavax or Shingrix are safe and effective in patients with rheumatoid arthritis (RA) currently using anti-tumor necrosis factor (TNF) therapies. Inclusion/exclusion criteria for this sub-study mirror that of the parent VERVE trial with the exception of abatacept therapy being allowed. Preliminary data from the VERVE parent protocol enrolling patients using anti-TNF therapy is encouraging in that few patients experienced adverse events (56 adverse events in 50 participants, out of 140 participants in total) and that 96.2% of these adverse events were considered either mild or moderate. Importantly, there have been no instances of vaccine dissemination or zoster events to date.
Conditions Studied
Interventions
- BIOLOGICAL Varicella Zoster Vaccine
- OTHER Placebo Injection
Study Locations (5)
Idaho
- St. Luke's Health System - Boise
Minnesota
- St. Paul Rheumatology - Eagan
New Mexico
- Jayashree Sinha, MD - Clovis
Oregon
- Oregon Health & Science University - Portland
Tennessee
- Arthritis Associates - Hixson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2014-05-08 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604406
The ClinicalTrials.gov registry entry for NCT03604406 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Kevin Winthrop, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Varicella Zoster Vaccine is the first listed.
NCT03604406 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Idaho, Minnesota, New Mexico.
Frequently Asked Questions
What is clinical trial NCT03604406 about?
NCT03604406 is a clinical study titled "The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept". This investigator-initiated study will serve as a sub-study for the American College of Rheumatology-sponsored VERVE protocol currently funded by the NIH. This double-blinded multicenter randomized pragmatic trial is designed to determine whether Zostavax or Shingrix are safe and effective in patien...
What is the current status of trial NCT03604406?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2014-05-08. Estimated completion is 2026-02.
What conditions does trial NCT03604406 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Herpes Zoster, Inflammatory Disease.
What interventions are being tested in trial NCT03604406?
The interventions under investigation include: Varicella Zoster Vaccine (BIOLOGICAL), Placebo Injection (OTHER).
Who is sponsoring clinical trial NCT03604406?
This trial is sponsored by Kevin Winthrop, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03604406 being conducted?
This trial has 5 study locations across Idaho, Minnesota, New Mexico, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.